Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart drug may keep AFib away after ablation in seniors

NCT ID NCT05528419

Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a combination drug (sacubitril/valsartan) can stop atrial fibrillation from returning after a heart procedure called catheter ablation. The study included 320 older adults (ages 55-80) with high blood pressure and atrial fibrillation. Participants took either the combination drug or a standard blood pressure medication (valsartan) for 12 months to see which better prevents heart rhythm problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

320 people

The number who actually took part.

Started

Feb 2023

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 55-80; 2. Persistent ot paroxysmal atrial fibrillation patients who are going to receive catheter ablation surgery; 3. Clinic systolic blood pressure (SBP) ≥ 130 or diastolic blood pressure (DBP) ≥ 80 mmHg) in untreated and treated patients； 4. Ability to understand the study requirements and provide informed consent. Exclusion Criteria: 1. Secondary hypertension; 2. Clinic SBP/DBP≥180/110 mmHg, or 24-h ambulatory mean SBP/DBP\<120/70 mmHg; 3. Coronary heart disease, valvular heart disease, hypertrophic cardiomyopathy, pulmonary heart disease, hyperthyroidism or hypothyroidism; 4. New York Heart Association functional class IV, or left ventricular ejection fraction of \<30%; 5. Implanted pacemaker or defibrillator, myocardial infarction or percutaneous coronary intervention of ≤ 6 months before ablation; 6. Presence of LA thrombus on transesophageal echocardiography; 7. Severe hepatic or severe renal dysfunction estimated glomerular filtration rate of \< 30 mL/min\*per1.73 m2; 8. Serum potassium \>5.5 mmol/L; 9. Pregnant or lactating women; 10. Other circumstances that patients are not appropriate for the study upon the investigator's judgment; 11. Patients who are receiving other study drugs or study medical devices; 12. Unwilling or unable to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation recurrent are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation recurrent Hypertension

Contacts and locations

Locations

  • Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.